AFT Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

AFT Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 23.6% bzw. 12.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 24.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.9% betragen.

Wichtige Informationen

23.6%

Wachstumsrate der Gewinne

24.8%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	46.6%
Wachstumsrate der Einnahmen	12.4%
Zukünftige Eigenkapitalrendite	17.9%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25

Recent updates

AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 17

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Jul 26

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21

Gewinn- und Umsatzwachstumsprognosen

NZSE:AFT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (NZD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	295	26	25	14	3
3/31/2026	264	23	17	12	3
3/31/2025	223	15	12	11	3
9/30/2024	199	12	17	26	N/A
6/30/2024	197	14	18	27	N/A
3/31/2024	195	16	19	29	N/A
12/31/2023	185	13	12	21	N/A
9/30/2023	175	11	4	13	N/A
6/30/2023	166	11	3	12	N/A
3/31/2023	157	11	2	12	N/A
12/31/2022	149	14	4	12	N/A
9/30/2022	141	17	6	13	N/A
6/30/2022	135	18	7	14	N/A
3/31/2022	130	20	9	14	N/A
12/31/2021	125	15	7	12	N/A
9/30/2021	120	11	5	10	N/A
6/30/2021	116	9	0	6	N/A
3/31/2021	113	8	-5	1	N/A
12/31/2020	110	5	-4	3	N/A
9/30/2020	107	3	-2	6	N/A
6/30/2020	107	7	3	10	N/A
3/31/2020	106	12	8	15	N/A
12/31/2019	100	11	7	12	N/A
9/30/2019	94	11	5	9	N/A
6/30/2019	89	4	1	5	N/A
3/31/2019	85	-3	-2	1	N/A
12/31/2018	84	-7	-5	-1	N/A
9/30/2018	83	-11	-8	-4	N/A
6/30/2018	82	-12	N/A	-6	N/A
3/31/2018	81	-14	N/A	-9	N/A
12/31/2017	79	-14	N/A	-13	N/A
9/30/2017	76	-14	N/A	-16	N/A
6/30/2017	73	-16	N/A	-18	N/A
3/31/2017	69	-18	N/A	-19	N/A
12/31/2016	67	-18	N/A	-20	N/A
9/30/2016	64	-18	N/A	-21	N/A
6/30/2016	64	-16	N/A	-17	N/A
3/31/2016	64	-13	N/A	-14	N/A
12/31/2015	63	-13	N/A	-12	N/A
9/30/2015	62	-13	N/A	-10	N/A
6/30/2015	59	-13	N/A	-11	N/A
3/31/2015	56	-13	N/A	-13	N/A
3/31/2014	49	-1	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AFTDas prognostizierte Gewinnwachstum (23.6% pro Jahr) liegt über der Sparquote (3%).

Ertrag vs. Markt: AFTDie Erträge des Unternehmens (23.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt NZ (24.6% pro Jahr).

Hohe Wachstumserträge: AFTEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: AFTDie Einnahmen des Unternehmens (12.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt NZ (4.3% pro Jahr).

Hohe Wachstumseinnahmen: AFTDie Einnahmen des Unternehmens (12.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AFTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.9%).

AFT Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 24% to NZ$4.60

Price target increased by 24% to NZ$4.60

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Recent updates

AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Investor sentiment deteriorates as stock falls 17%

Price target increased by 24% to NZ$4.60

AFT Pharmaceuticals Limited to Report First Half, 2025 Results on Nov 21, 2024

Price target increased by 24% to NZ$4.60

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Upcoming dividend of NZ$0.016 per share

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 02, 2024

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Dividend of NZ$0.016 announced

Full year 2024 earnings released: EPS: NZ$0.15 (vs NZ$0.10 in FY 2023)

AFT Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 23, 2024

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited to Report First Half, 2024 Results on Nov 23, 2023

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Announces Board Changes

Independent Non-Executive Director recently sold NZ$109k worth of stock

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Consensus EPS estimates fall by 17%

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year Ending March 2024

AFT Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 22, 2023

Price target decreased to NZ$4.22

Consensus forecasts updated

First half 2023 earnings released: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Price target decreased to NZ$5.51

AFT Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 24, 2022

AFT Pharmaceuticals Limited Update on Maxigesic IV Us Registration Filing

AFT Pharmaceuticals Limited Completes Pascomer Clinical Study

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

US FDA Seeks More Information on AFT Pharmaceuticals Limited's Maxigesic IV Application

Price target decreased to NZ$4.40

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Investor sentiment improved over the past week

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year to 31 March 2023

AFT Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 23, 2022

Price target increased to NZ$5.88

AFT Pharmaceuticals Announces US Food and Drug Administration Approve Topical Treatment Indicated for Facial Angiofibroma

Independent Director recently bought NZ$66k worth of stock

Independent Director recently bought NZ$171k worth of stock

AFT Pharmaceuticals Limited Welcomes Australian Federal Court Appeal Success

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

First half 2022 earnings released: EPS NZ$0.04 (vs NZ$0.01 in 1H 2021)

Price target increased to NZ$5.88

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

AFT Pharmaceuticals Got First Regulatory Approval of Maxigesic Oral Liquid in Europe

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Full year 2021 earnings released

AFT Pharmaceuticals Limited Announces Earnings Guidance for the Fiscal Year 2022

CFO & Company Secretary exercised options to buy NZ$205k worth of stock.

Consensus EPS estimates fall to NZ$0.092

Price target decreased to NZ$4.95

AFT Pharmaceuticals Revises Earnings Guidance for the Year to 31 March 2021

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

AFT Pharmaceuticals Signs an Exclusive Maxigesic IV Licensing Agreement for Eight New European Markets

New 90-day low: NZ$4.21

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

New 90-day high: NZ$5.51

AFT Pharmaceuticals Limited Appoints Anita Baldauf as Non-Executive Director